Teresa Conner-Kerr, associate professor of physical therapy, has supported the successful filing of a 510 K FDA application for a new wound management technology, MIST Therapy(TM) System 5.0 Wound Treatment Device, developed by Celleration, Inc., Eden Prairie, Minn.
The U.S. Food and Drug Administration (FDA) approved the application in July and cleared Celleration, Inc. to begin marketing the MIST Therapy System. Conner-Kerr conducted a preclinical trial to test the efficacy of this system in wound debridement and bacterial reduction using a porcine full-thickness skin model. She also participated as an investigator in the comparative prospective, randomized, double-masked, parallel group, controlled trial comparing Celleration MIST™ therapy to sham therapy in individuals with diabetic neuropathic ulcers. Results of this trial are currently being analyzed.